Sunday, October 10, 2010

Glaxo's Avandia Cover-Up

Glaxo's Avandia Cover-Up

An ex-Senate investigator reveals how GlaxoSmithKline sought to conceal evidence linking its blockbuster diabetes drug to heart attacks.
Links:
[1] http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=true
[2] http://www.nytimes.com/2010/09/24/health/policy/24avandia.html
[3] http://www.washingtonpost.com/wp-dyn/content/article/2010/02/20/AR2010022003547.html
[4] http://en.wikipedia.org/wiki/Steven_Nissen
[5] http://www.nejm.org/doi/pdf/10.1056/NEJMoa072761
[6] http://www.usatoday.com/news/health/2007-06-06-avandia-black-box_N.htm
[7] http://finance.senate.gov/newsroom/chairman/release/?id=bc56b552-efc5-4706-968d-f7032d5cd2e4
[8] http://www.nejm.org/doi/full/10.1056/NEJM200010193431603
[9] http://www.gsk.com/investors/annual-reports-archive.htm
[10] http://www.allbusiness.com/technology/778004-1.html
[11] http://www.baventurepartners.com/downloads/news/stroke_approval.pdf
[12] http://www.bloomberg.com/news/2010-07-13/glaxosmithkline-is-said-to-pay-460-million-to-settle-avandia-damage-suits.html
[13] http://blogs.nature.com/news/thegreatbeyond/2010/09/avandia_pulled_in_europe_restr.html

No comments: